Jassem J, Karnicka-Młodkowska H, Jassem E, Słupek A, Zych J, Wiatr E, Malak S, Moś-Antkowiak R, Szymaczek-Meyer L, Pilarska-Machowicz A
Department of Oncology and Radiotherapy, Gdansk Medical School, Poland.
Lung Cancer. 1994 Sep;11(3-4):283-91. doi: 10.1016/0169-5002(94)90548-7.
From March 1987 to February 1991, 136 patients with untreated small cell lung cancer (64 patients with limited disease and 72 with extensive disease), were treated as part of a prospective multi-center study, with a combination of cyclophosphamide 1000 mg/m2 i.v. on day 1, epirubicin 70 mg/m2 i.v. on day 1 and etoposide 100 mg/m2 i.v. on days 1, 3 and 5. Courses were repeated every 3 weeks. One-hundred thirty-four patients were evaluable. There were 42 (31%) complete responses and 66 (49%) partial responses for an overall response rate of 80% (95% confidence interval 71-87%). A complete response was seen in 24 patients (38%) with limited disease and in 18 patients (26%) with extensive disease, while a partial response was observed for 31 (48%) and in 35 (50%) patients, respectively. The median duration of response for all patients was 8.9 months (range, 1-60+ months). The median duration of survival for the entire group was 11.4 months (12.5 months for limited disease and 9.8 months for extensive disease). The 2-year survival rate for the whole group was 13%. The main side-effects were myelosuppression, alopecia, nausea and vomiting. Grade 4 toxicity was seen in 8.5% of patients. In conclusion, the studied regimen was found to be active and well tolerated and may be considered as an alternative to standard chemotherapy combinations in SCLC.
1987年3月至1991年2月，136例未经治疗的小细胞肺癌患者（64例局限性疾病患者和72例广泛性疾病患者）作为一项前瞻性多中心研究的一部分接受治疗，采用环磷酰胺1000mg/m²静脉注射，第1天使用；表柔比星70mg/m²静脉注射，第1天使用；依托泊苷100mg/m²静脉注射，第1、3和5天使用。每3周重复疗程。134例患者可评估。有42例（31%）完全缓解，66例（49%）部分缓解，总缓解率为80%（95%置信区间71-87%）。24例（38%）局限性疾病患者和18例（26%）广泛性疾病患者出现完全缓解，而分别有31例（48%）和35例（50%）患者出现部分缓解。所有患者的中位缓解持续时间为8.9个月（范围1-60+个月）。整个组的中位生存时间为11.4个月（局限性疾病患者为12.5个月，广泛性疾病患者为9.8个月）。整个组的2年生存率为13%。主要副作用为骨髓抑制、脱发、恶心和呕吐。8.5%的患者出现4级毒性。总之，所研究的方案被发现具有活性且耐受性良好，可被视为小细胞肺癌标准化疗联合方案的替代方案。
